Selank vs Benzodiazepines: What the Russian Head-to-Head Trials Actually Compared

Benzodiazepines are the most prescribed class of anxiolytics in the world. They also come with a known cost: sedation, motor impairment, cognitive dulling, anterograde amnesia, dependence, and a withdrawal syndrome that can be medically dangerous. These are not rare side effects. They are the predictable downstream of the mechanism.

Selank is a seven-residue synthetic peptide. The Russian Federation registers it as an anxiolytic for generalized anxiety disorder. Its publication record — almost entirely Russian-language — includes direct head-to-head comparisons against benzodiazepines. The reported outcome of those comparisons is the reason the comparison is interesting in the first place: anxiolytic efficacy in the same range as short-course benzodiazepine therapy, with a categorically different side-effect signature.

This article walks through what those Russian trials actually measured, why the mechanism predicts the difference in side effects, and the structural limits of the evidence base. The point is not to recommend Selank over benzodiazepines — that recommendation would be irresponsible from a Western evidence-standards perspective. The point is to read the comparison honestly.

Selank is supplied by PepMax under the slug selank for laboratory research use only. It is not approved by FDA, EMA, MHRA, or Health Canada for any human or veterinary therapeutic use.

Why the comparison gets made at all

Two facts make the comparison structurally interesting rather than a marketing contrivance.

First, both compounds are anxiolytic via the GABAergic system. Benzodiazepines act on GABA-A receptors at a well-characterized allosteric site. Selank’s anxiolytic effect in animal and human studies is most consistently attributed to GABAergic modulation as well, though through a different binding interaction^[2][3]. That overlap is what makes the head-to-head clinically meaningful: same neurotransmitter axis, different molecular access point.

Second, the side-effect profiles diverge sharply.The known liabilities of benzodiazepines — sedation, motor impairment, dependence, anterograde amnesia, rebound anxiety on discontinuation — are absent or minimal in the Selank literature. If the divergence is real, it tells you something about how finely-grained GABA-A pharmacology can be^[8]. If it is artifact of single-program reporting, it tells you something about the evidence base. Either way, the question is worth asking.

Two drug classes, one neurotransmitter system

Benzodiazepines — the BZD-site model

Benzodiazepines (diazepam, alprazolam, lorazepam, clonazepam, medazepam, and dozens more) bind a specific allosteric site on the GABA-A receptor: the benzodiazepine site, which sits at the interface of the α and γ2 subunits of pentameric GABA-A pentamers. Binding does not open the chloride channel directly. It increases the channel’s opening frequency in the presence of GABA, amplifying inhibitory neurotransmission throughout the central nervous system^[7].

Because the BZD site is present on GABA-A pentamers containing different α subunits (α1, α2, α3, α5), and because those subtypes are distributed across brain regions with different functions, the same molecular event produces a bundle of effects from the same drug: anxiolysis (α2/α3 subtypes), sedation and motor impairment (α1), amnesia (α1 again), and muscle relaxation (multiple subtypes)^[8]. This is why a single benzodiazepine produces sedation as a near-inevitable companion to anxiolysis — the receptor architecture does not separate the two cleanly.

Dependence and tolerance follow from the same mechanism. Chronic potentiation of GABA-A signaling triggers compensatory downregulation; abrupt discontinuation leaves the system hyperexcitable, producing the rebound-anxiety and withdrawal-seizure spectrum that defines benzodiazepine discontinuation syndrome^[9][10].

Selank — GABAergic, but not at the BZD site

Selank is a metabolically stabilized analog of tuftsin (Thr–Lys–Pro–Arg), a four-residue immunomodulatory peptide originally characterized as a fragment of the IgG heavy chain^[11]. The Russian Academy program appended the Pro–Gly–Pro tail used across the Ashmarin–Myasoedov peptide family to confer protease resistance, yielding the seven-residue Selank sequence (Thr–Lys–Pro–Arg–Pro–Gly–Pro)^[1].

The mechanistic claim made consistently in the Russian Selank literature is that Selank modulates GABAergic signaling withoutbinding the benzodiazepine site. Volkova and colleagues (2016) frame this as the core pharmacological distinction: Selank achieves a benzodiazepine-range anxiolytic phenotype through a different molecular interaction with the GABA-A system, and as a result does not produce the α1-subtype-mediated sedation and motor effects that come bundled with classical benzodiazepines^[2]. The precise binding biochemistry — whether Selank acts directly on GABA-A pentamers, on an upstream GABAergic regulator, or via the enkephalin pathway discussed below — remains less completely characterized than the BZD-site model.

This is the central asymmetry of the comparison. Benzodiazepine pharmacology is one of the most thoroughly mapped systems in neuropharmacology. Selank’s GABAergic mechanism is reported in the Russian literature as “non-benzodiazepine,” which is a negative characterization — it tells you what Selank is not doing, not what it is doing at the level of receptor occupancy.

Side-by-side data sheet

Read the two pharmacologies in parallel. The class entries for benzodiazepines below describe the class as a whole; individual benzodiazepines vary in potency, half-life, and clinical positioning.

The head-to-head Russian trials

Three reports anchor the clinical comparison. All three are in Russian-language journals; all three come from labs within the Ashmarin–Myasoedov institutional network. They are the entirety of the head-to-head record as of this writing.

Zozulya 2008 — Selank vs medazepam in GAD

Zozulya and colleagues (2008) reported a clinical study of Selank in patients with generalized anxiety disorder and neurasthenia, with the benzodiazepine medazepam as a comparator^[3]. The endpoints were standard psychiatric anxiety scales applied longitudinally over a treatment course of approximately 14 days. The headline finding reported in the paper is that intranasal Selank reached an anxiolytic response in the same range as medazepam, while differing in two important respects:

• Onset profile. Medazepam produced earlier sedation and earlier subjective calming; Selank produced a more gradual onset of anxiolytic effect without the sedation component.
• Side-effect signature. The Selank arm did not report the sedation, motor impairment, or anterograde-amnesia complaints associated with the medazepam arm. No withdrawal syndrome was reported on Selank discontinuation; the paper does not establish dependence-syndrome equivalence definitively, but the absence is consistent across follow-up.

The paper is the most cited source for the Russian regulatory case that Selank deserves registration as an anxiolytic. It is also the source most quoted, often out of context, in Western secondary writing that calls Selank a “benzodiazepine alternative.” The trial is not a Western Phase 3 trial. It is not blinded to modern Western standards. Its outcomes have not been independently replicated in a peer-reviewed Western journal. Read it as the strongest evidence in the Russian record — not as a settled answer.

Volkova 2016 — comparative analysis with the BZD class

Volkova and colleagues (2016) published a comparative pharmacological analysis of Selank against the benzodiazepine class as a whole^[2]. The paper synthesizes the mechanistic and clinical literature available at the time and positions Selank within the anxiolytic landscape. The key claims:

• Selank’s anxiolytic activity is comparable in clinical magnitude to short-course benzodiazepine therapy in the specific indications studied (generalized anxiety disorder, neurasthenia).
• The GABAergic action of Selank does not occur at the benzodiazepine binding site; the mechanism is described as non-BZD-site allosteric.
• The absence of the sedation, dependence, and rebound-withdrawal profile is a direct consequence of the mechanistic divergence, not an empirical accident.

Volkova 2016 is a review and synthesis rather than a primary head-to-head trial. Its weight derives from the consistency of the underlying primary literature, not from new statistical comparison. A Western reader should treat it as the most useful single entry point to the Russian record — with the caveat that it is written from within the program that developed Selank.

Medvedev 2015 — Selank as adjunct in mixed anxiety

Medvedev and colleagues (2015) reported on Selank in clinical practice as an adjunct to standard pharmacotherapy in mixed anxiety disorders^[4]. The paper’s contribution to the benzodiazepine comparison is indirect but important: it describes Selank being used to taper or replace benzodiazepine therapy in patients with established benzodiazepine exposure, without the rebound-anxiety spike that typically accompanies benzodiazepine withdrawal. The clinical context (post-Soviet Russian psychiatric practice) is not directly comparable to Western prescribing, and the report is observational rather than randomized, but the directional finding is consistent with the mechanistic story.

Where the side-effect profiles diverge

The most clinically interesting part of the comparison is the divergence in side effects, because that is what would justify a different drug in the first place. Anxiolytic efficacy without sedation and without dependence is a thing physicians have wanted for decades; the buspirone-class partial 5-HT₁₀ agonists addressed some of it but with weaker acute efficacy. The Russian literature positions Selank as filling the same niche from a different molecular direction.

The mechanistic prediction is clean: if the α1-mediated effects (sedation, amnesia, motor impairment) require the benzodiazepine site, and Selank does not occupy that site, then those effects should not appear. The Russian clinical record is consistent with the prediction. Whether the prediction generalizes outside the 14-day treatment windows and the GAD/neurasthenia indication is an open question that the existing evidence base does not answer.

Selank’s second pathway — enkephalin protection

One pathway Selank engages that benzodiazepines do not is the inhibition of enkephalin-degrading enzymes. Kost and colleagues (2001) reported that Selank (and Semax) inhibit leucine aminopeptidase and angiotensin-converting enzyme in human serum, prolonging the half-life of endogenous enkephalins^[5]. Enkephalins are short opioid peptides with documented roles in stress reactivity, affective tone, and the descending modulation of pain.

This is mechanistically distinct from benzodiazepine action. Benzodiazepines do not touch the endogenous opioid system. The clinical contribution of the enkephalin pathway to Selank’s overall phenotype is not fully quantified, but the pathway is a plausible part of the explanation for why Selank produces a calming effect without the BZD-typical bundle — the GABAergic modulation provides the anxiolytic floor, and the enkephalin pathway provides a separable affective lift.

Kozlovskii and Danchev (2003) reported that Selank optimized performance on a conditioned active-avoidance task in rats: the animals retained learning and performance, but with reduced stress signature and no motor impairment^[6]. This pattern — calming without dulling — is consistent with the two-pathway story.

Structural limitations of the comparison

Three limitations apply to every claim above. A researcher evaluating this evidence for any decision — even a research-program design decision — should weigh them explicitly.

First, single-program literature.The Selank evidence base is concentrated almost entirely in the Ashmarin–Myasoedov institutional network at the Institute of Molecular Genetics of the Russian Academy of Sciences and affiliated clinical centers. This is the same pattern that applies to BPC-157 (the Sikirić group at Zagreb) — the literature is large enough to be internally consistent and small enough that independent replication is not yet a feature of the evidence base.

Second, language and venue concentration. The majority of clinical Selank work is published in Russian, principally in Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. ClinicalTrials.gov and EudraCT do not contain registered Phase 3 trials of Selank against benzodiazepines. A Western researcher reading only English-language sources will see a small fraction of the actual record.

Third, indication and duration scope. The Russian comparisons are anchored in generalized anxiety disorder and neurasthenia at treatment durations of roughly two weeks. Long-term Selank use, acute panic, alcohol-withdrawal management, seizure-prophylaxis indications, and pediatric/geriatric populations are not part of the comparative record. Extrapolation beyond the studied window is not supported by the data, only by mechanism.

Regulatory status and what this article is not

The reason to write this article is not to recommend a substitution. The reason is that the comparison gets made constantly in informal channels — on forums, in marketing copy, in podcast summaries — and the underlying Russian literature deserves an honest read rather than either a credulous restatement or a reflexive dismissal. The literature exists. The head-to-head trials exist. The mechanistic story is internally coherent. The structural limitations are real. All of that should be visible at the same time.

Further reading

The most useful primary entry points to this comparison, in English where possible: Volkova and colleagues (2016) for the synthesis^[2]; Zozulya and colleagues (2008) for the GAD trial^[3]; Kost and colleagues (2001) for the enkephalin-pathway pharmacology shared between Selank and Semax^[5]. For the benzodiazepine side: Möhler, Fritschy, and Rudolph (2002) for the BZD-site mechanism^[7]; Olsen and Sieghart (2009) for the GABA-A subtype landscape^[8]; Lader (2011) for the dependence-and-withdrawal review^[9].

Companion PepMax research articles cover related ground: Semax vs Selank for the full structural and mechanistic comparison of the two Russian heptapeptides; What ≥99% purity actually means for the analytical-quality questions that apply to every peptide we ship; and How we verify peptide purity for the HPLC and mass-spectrometry workflow used on every Selank lot.